Health Technology · Pharmaceuticals: Major · NSE: RPGLIFE · data 2026-10-09
RPG Life Sciences Limited
Health check: Strong (7.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,719.2
Market cap
₹4,646 cr
P/E
37.6
P/B
—
ROE
20.3%
ROCE
21.3%
Debt / equity
0.03
Dividend yield
0.85%
1-year return
20.1%
52-week high
₹3,127.8
52-week low
₹1,733
Operating margin
18.1%
Growth
| Revenue (last 12 months) | ₹734 cr |
| Net profit (last 12 months) | ₹120 cr |
| Sales growth, 3 years (yearly) | 11.3% |
| Profit growth, 3 years (yearly) | 19.4% |
Similar companies
FDC Ltd. (FDC) · Novartis India Limited (NOVARTIND) · Gujarat Themis Biosyn Ltd (GUJTHEM) · SMS Pharmaceuticals Limited (SMSPHARMA) · Gufic Biosciences Limited (GUFICBIO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open RPGLIFE in NSE Scanner →